Effect of HU Treatment In Vivo on KTLS Cells
| Treatment (mg/kg/d) . | No. of BM Cells in Long Bones . | KTLS Cells (%) . | Estimated No. of KTLS Cells . | KTLS Cells (%) in S/G2/M . |
|---|---|---|---|---|
| 1 day | ||||
| Control | 3.1 ± 1.2 × 107 | 0.06* | 1.7 × 104* | 4.8 ± 2.4 |
| 10 | 3.6 ± 1.1 × 107 | 0.06 ± 0.005 | 1.9 ± 0.3 × 104 | 5.2 ± 1.2 |
| 50 | 2.9 ± 1.0 × 107 | 0.07 ± 0.01 | 1.7 ± 0.5 × 104 | 5.8 ± 1.3 |
| 100 | 3.0 ± 0.9 × 107 | 0.07 ± 0.01 | 1.8 ± 0.8 × 104 | 6.2 ± 2.7 |
| 3 days | ||||
| Control | 3.7 ± 1.2 × 107 | 0.06 ± 0.02 | 2.4 ± 0.8 × 104 | 7.3 ± 0.7 |
| 10 | 4.0 ± 1.3 × 107 | 0.07 ± 0.01 | 2.9 ± 1.1 × 104 | 7.5 ± 2.0 |
| 50 | 2.8 ± 1.2 × 107 | 0.13 ± 0.02 | 3.8 ± 2.0 × 104 | 14.5 ± 3.4 |
| 100 | 1.7 ± 0.5 × 107 | 0.34 ± 0.02 | 6.0 ± 2.0 × 104 | 22.2 ± 6.2 |
| 5 days | ||||
| Control | 3.3 ± 0.6 × 107 | 0.05 ± 0.004 | 1.7 ± 0.3 × 104 | 3.3 ± 1.6 |
| 10 | 4.0 ± 0.6 × 107 | 0.07 ± 0.01 | 2.6 ± 0.1 × 104 | 6.5 ± 3.5 |
| 50 | 3.2 ± 1.1 × 107 | 0.10 ± 0.01 | 3.6 ± 0.4 × 104 | 5.2 ± 0.4 |
| 100 | 2.3 ± 0.7 × 107 | 0.26 ± 0.1 | 5.7 ± 1.2 × 104 | 4.4 ± 2.7 |
| Treatment (mg/kg/d) . | No. of BM Cells in Long Bones . | KTLS Cells (%) . | Estimated No. of KTLS Cells . | KTLS Cells (%) in S/G2/M . |
|---|---|---|---|---|
| 1 day | ||||
| Control | 3.1 ± 1.2 × 107 | 0.06* | 1.7 × 104* | 4.8 ± 2.4 |
| 10 | 3.6 ± 1.1 × 107 | 0.06 ± 0.005 | 1.9 ± 0.3 × 104 | 5.2 ± 1.2 |
| 50 | 2.9 ± 1.0 × 107 | 0.07 ± 0.01 | 1.7 ± 0.5 × 104 | 5.8 ± 1.3 |
| 100 | 3.0 ± 0.9 × 107 | 0.07 ± 0.01 | 1.8 ± 0.8 × 104 | 6.2 ± 2.7 |
| 3 days | ||||
| Control | 3.7 ± 1.2 × 107 | 0.06 ± 0.02 | 2.4 ± 0.8 × 104 | 7.3 ± 0.7 |
| 10 | 4.0 ± 1.3 × 107 | 0.07 ± 0.01 | 2.9 ± 1.1 × 104 | 7.5 ± 2.0 |
| 50 | 2.8 ± 1.2 × 107 | 0.13 ± 0.02 | 3.8 ± 2.0 × 104 | 14.5 ± 3.4 |
| 100 | 1.7 ± 0.5 × 107 | 0.34 ± 0.02 | 6.0 ± 2.0 × 104 | 22.2 ± 6.2 |
| 5 days | ||||
| Control | 3.3 ± 0.6 × 107 | 0.05 ± 0.004 | 1.7 ± 0.3 × 104 | 3.3 ± 1.6 |
| 10 | 4.0 ± 0.6 × 107 | 0.07 ± 0.01 | 2.6 ± 0.1 × 104 | 6.5 ± 3.5 |
| 50 | 3.2 ± 1.1 × 107 | 0.10 ± 0.01 | 3.6 ± 0.4 × 104 | 5.2 ± 0.4 |
| 100 | 2.3 ± 0.7 × 107 | 0.26 ± 0.1 | 5.7 ± 1.2 × 104 | 4.4 ± 2.7 |
Mice were treated continuously with 10, 50, or 100 mg/kg/d HU for 1, 3, or 5 days. BM cells were harvested from 4 long bones from each mouse. About 3 to 5 mice were used for each group, and results were pooled from 17 independent experiments. In each experiment, the no. of BM cells, % KTLS cells in BM, no. of KTLS cells in BM, or % KTLS cells in the S/G2/M phases of the cell cycle were determined. Data represent the mean ± SD. Mice in control groups were treated only with PBS. One-day HU treatment, 10 v 100 mg/kg/d: P > .37 for no. of BM cells, P > .50 for % KTLS cells in BM, P > .83 for no. of KTLS cells, and P > .45 for % KTLS cells in S/G2/M. Three-day HU treatment, control v 100 mg/kg/d: P < .001 (statistically significant [SS]) for no. of BM cells, P < .0001 (SS) for % KTLS cells in BM, P < .005 (SS) for no. of KTLS cells, and P < .0001 (SS) for % KTLS cells in S/G2/M. Five-day HU treatment, control v 100 mg/kg/d: P > .07 for no. of BM cells, P < .05 (SS) for KTLS frequency, P < .005 (SS) for no. of KTLS cells, and P > .60 for % KTLS cells in S/G2/M. Three-day 100 mg/kg/d HU v five-day 100 mg/kg/d HU: P > .17 for no. of BM cells, P > .09 for % of KTLS cells in BM, P > .84 for no. of KTLS cells, and P < .001 (SS) for % KTLS cells in S/G2/M.
Data based on 1 experiment; results are consistent with previous reports.43